Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 1029-1039

  Capkun, Gorana ^a   Lahoz, Raquel ^a   Verdun, Elisabetta ^a   Song, Xue ^b   Chen, Weston ^c   Korn, Jonathan R ^d   Dahlke, Frank ^a   Freitas, Rita ^e   Fraeman, Kathy ^f   Simeone, Jason ^f   Johnson, Barbara H ^b   Nordstrom, Beth ^f  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IBM WATSON HEALTH   (United States)

^c Novartis Pharma Co Ltd Ltd   (China)

^d IQVIA   (United States)

^e WELLMERA AG   (Switzerland)

^f EVIDERA   (United States)

Author keywords

Administrative claims; Algorithm; Multiple sclerosis; Real world evidence; Relapse

Indexed keywords

ADMINISTRATIVE CLAIM DATABASE; ALGORITHM; CLINICAL PRACTICE; CONFERENCE PAPER; DATA BASE; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; FOLLOW UP; GOVERNMENT; HOSPITALIZATION; HUMAN; ICD-9-CM; MARKETSCAN; MEDICAL ETHICS; METHODOLOGY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PATIENT SELECTION; PHARMETRICS; QUESTIONNAIRE; RECURRENCE RISK; RELAPSE; ADULT; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; UNITED STATES; VALIDATION STUDY;

ADULT; ALGORITHMS; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; UNITED STATES;

EID: 84928192323     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1014029     Document Type: Conference Paper

References (34)

1. Multiple Sclerosis International Federation. Atlas of MS database, 2013. Available at: http://www.atlasofms.org/index.aspx [Last accessed 23 April 2014]
2. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 (Pt 1):133-46
4. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
5. Rojas JI, Romano M, Ciapponi A, et al. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev 2010 Jan 20;(1):CD006643. doi: 10.1002/14651858.CD006643.pub3
6. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
7. Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011;28:761-75
8. Kleinman NL, Beren IA, Rajagopalan K, Brook RA. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40
9. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
10. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
11. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
12. Rajagopalan K, Brook RA, Beren IA, Kleinman NL. Comparing costs and absences for multiple sclerosis among US employees: pre-and post-treatment initiation. Curr Med Res Opin 2011;27:179-88
13. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
14. World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification, 2010. Available at: http://www.cdc.gov/ nchs/icd/icd9cm.htm [Last accessed 23 April 2014]
15. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ 2010;13:464-71
16. Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 2008;40:281-90
17. Dorrance KA, Ramchandani S, Neil N, Fisher H. Leveraging the military health system as a laboratory for health care reform. Mil Med 2013;178:142-5
18. Epstein M, International Society of P. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005;14:589-95
19. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45:247-51
20. Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465-71
21. Ingenix Normative Health Information Database. Available at: http://www. optum.com/life-sciences/develop-evidence/data-assets.html [Last accessed 30 April 2013]
22. Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122
23. National Multiple Sclerosis Society. MS prevalence. Available at: http:// www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx [Last accessed 22 June 2013]
24. Capkun G, Lahoz R, Nordstrom B, et al. Exploring the identification of multiple sclerosis incident cohorts in claims databases: methodology and challenges. Value Health 2013;16:A582
25. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69: 292-302
26. Capkun-Niggli G, Lahoz R, Verdun E, et al. Medical and pharmacy claimsbased algorithms for identifying relapses in patients with multiple sclerosis. Value Health 2013;16:A582
27. Bergvall N, Lahoz R, Reynolds T, Korn JR. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2014; 30:1461-71
28. Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2013;29:1647-56
29. Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One 2014;9:e88472
30. Bergvall N, Petrilla A, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ 2014;17:696-707
31. Novartis Pharma AG. Real-world Relapse and Hospitalization Rates in Multiple Sclerosis Literature Search. 2013
32. Spelman T, Bergvall N, Tomic D, et al. Real-world comparative effectiveness of fingolimod and interferon/glatiramer therapies in a switch population using propensity-matched data from MSBase. Poster (P1096) presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2-5 October 2013, Copenhagen, Denmark
33. Capkun G, Lahoz R, Chen W, et al. Comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US MarketScan Database. Mult Scler 2014; 20(Suppl 1):147
34. Capkun G, Nordstrom B, Lahoz R, et al. Mortality and morbidity in patients with multiple sclerosis compared with the general population: a retrospective analysis using the US Department of Defense Database. Mult Scler 2013;19(Suppl 1):349